Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes

References

• FeenyDPreference-based measures: utility and quality-adjusted life yearsFayersPHaysRAssessing Quality of Life in Clinical Trials2nd edNew YorkOxford University Press2005405431
   Google Scholar
• TorranceGWMeasurement of health state utilities for economic appraisalJ Health Econ1986513010311607
   PubMed Web of Science ®Google Scholar
• BrazierJRRatcliffeJSalomonJATsuchiyaAMeasuring and Valuing Health Benefits for Economic EvaluationNew YorkOxford University Press2007
   Google Scholar
• FuscoFTurchettiGTelerehabilitation after total knee replacement in Italy: cost-effectiveness and cost-utility analysis of a mixed telerehabilitation-standard rehabilitation programme compared with usual careBMJ Open20166e009964
   PubMed Web of Science ®Google Scholar
• MarcellusiAVitiRRussoSAndreoniMAntinoriAMenniniFSEarly treatment in HIV patients: a cost-utility analysis from the Italian perspectiveClin Drug Investig201636377387
   Web of Science ®Google Scholar
• RuggeriMBasileMCorettiSDragoCCicchettiAEconomic analysis and budget impact of tenofovir and entecavir in the first-line treatment of hepatitis B virus in ItalyAppl Health Econ Health Policy20171547949028197805
   PubMed Web of Science ®Google Scholar
• SullivanSDCraxiAAlbertiACost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis CPharmacoeconomics20042225726514974875
   PubMed Web of Science ®Google Scholar
• ChevreulKGandreCBrighamKBSocial/economic costs and health-related quality of life in patients with fragile X syndrome in EuropeEur J Health Econ201617Suppl 1435227072054
   PubMed Web of Science ®Google Scholar
• KerrCLloydEJKosmasCEHealth-related quality of life in Parkinson’s: impact of “off” time and stated treatment preferencesQual Life Res2016251505151526627224
   PubMed Web of Science ®Google Scholar
• MozziAMeregagliaMLazzaroCTornatoreVBelfiglioMFattoreGA comparison of EuroQol 5-Dimension health-related utilities using Italian, UK, and US preference weights in a patient sampleClinicoecon Outcomes Res2016826727427358571
   PubMedGoogle Scholar
• MatzaLSBoyeKSStewartKDDaviesEWPaczkowskiRHealth state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetesBMC Health Serv Res20171777429178918
   PubMed Web of Science ®Google Scholar
• ArodaVRHenryRRHanJEfficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic reviewClin Ther2012341247.e221258.e2222608780
   PubMed Web of Science ®Google Scholar
• ArodaVRRatnerRThe safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a reviewDiabetes Metab Res Rev20112752854221484979
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care2012351364137922517736
   PubMed Web of Science ®Google Scholar
• NICEType 2 diabetes: the management of type 2 diabetesNICE Clinical Guideline 87London, UK52009 Last Modified: December 201454
   Google Scholar
• TranLZielinskiARoachAHPharmacologic treatment of type 2 diabetes: injectable medicationsAnn Pharmacother20154970071425802244
   PubMed Web of Science ®Google Scholar
• TrujilloJMNufferWEllisSLGLP-1 receptor agonists: a review of head-to-head clinical studiesTher Adv Endocrinol Metab20156192825678953
   PubMed Web of Science ®Google Scholar
• European Agency for Safety and Health at WorkDirective 2010/32/EU – prevention from sharp injuries in the hospital and healthcare sector52010 Available from: https://osha.europa.eu/en/legislation/directives/council-directive-2010-32-eu-prevention-from-sharp-injuries-in-the-hospital-and-healthcare-sectorAccessed January 13, 2016
   Google Scholar
• Health and Safety ExecutiveHealth and Safety (Sharp Instruments in Healthcare) Regulations 2013 – Guidance for employers and employeesLondon, UKHealth and Safety Executive (HSE)20136
   Google Scholar
• BoyeKSMatzaLSWalterKNVan BruntKPalsgroveACTynanAUtilities and disutilities for attributes of injectable treatments for type 2 diabetesEur J Health Econ20111221923020224930
   PubMed Web of Science ®Google Scholar
• MatzaLSBoyeKSYurginNUtilities and disutilities for type 2 diabetes treatment-related attributesQual Life Res2007161251126517638121
   PubMed Web of Science ®Google Scholar
• BeaudetAPalmerJLTimlinLCost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UKJ Med Econ20111435736621563878
   PubMedGoogle Scholar
• MittendorfTSmith-PalmerJTimlinLHappichMGoodallGEvaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German settingDiabetes Obes Metab2009111068107919732121
   PubMed Web of Science ®Google Scholar
• SamyshkinYGuillerminALBestJHBrunellSCLloydALong-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the USJ Med Econ201215Suppl 261322793669
   PubMedGoogle Scholar
• SinhaARajanMHoergerTPogachLCosts and consequences associated with newer medications for glycemic control in type 2 diabetesDiabetes Care20103369570020056950
   PubMed Web of Science ®Google Scholar
• NICE (National Institute for Health and Care Excellence)Process and Methods Guides: Guide to the Methods of Technology Appraisal 2013London, UKNICE2013
   Google Scholar
• AstraZeneca PharmaceuticalsInstructions for use – Bydureon Single-Dose Tray (exenatide extended-release) for injectable suspension13262014 Available from: http://www.azpicentral.com/bydureon/ifu_bydureon.pdf#page=1Accessed May 4, 2015
   Google Scholar
• Eli Lilly and CompanyInstructions for use: TRULICITY (dulaglutide) injection, for subcutaneous use 15 mg/05 mL Single-Dose Pen once weekly2015 Available from: http://pi.lilly.com/us/trulicity-highdose-ai-ifu.pdfAccessed May 4, 2015
   Google Scholar
• GlaxoSmithKline (GSK)Highlights of prescribing information: Tanzeum (albiglutide) for injection, for subcutaneous use1562015 Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tanzeum/pdf/TANZEUM-PI-MG-IFU-COMBINED.PDFAccessed May 5, 2015
   Google Scholar
• BrooksREuroQol: the current state of playHealth Policy199637537210158943
   PubMed Web of Science ®Google Scholar
• HerdmanMGudexCLloydADevelopment and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Qual Life Res2011201727173621479777
   PubMed Web of Science ®Google Scholar
• The EuroQol GroupEuroQol – a new facility for the measurement of health-related quality of lifeHealth Policy19901619920810109801
   PubMed Web of Science ®Google Scholar
• ScaloneLCortesiPACiampichiniRItalian population-based values of EQ-5D health statesValue Health20131681482223947975
   PubMed Web of Science ®Google Scholar
• JanssenMFLubetkinEISekhoboJPPickardASThe use of the EQ-5D preference-based health status measure in adults with Type 2 diabetes mellitusDiabet Med20112839541321392061
   PubMed Web of Science ®Google Scholar
• BrennanVKDixonSIncorporating process utility into quality adjusted life years: a systematic review of empirical studiesPharmacoeconomics20133167769123771494
   PubMed Web of Science ®Google Scholar
• MatzaLSSapraSJDillonJFHealth state utilities associated with attributes of treatments for hepatitis CEur J Health Econ2015161005101825481796
   PubMed Web of Science ®Google Scholar
• Hixson-WallaceJADotsonJBBlakeySAEffect of regimen complexity on patient satisfaction and compliance with warfarin therapyClin Appl Thromb Hemost20017333711190902
   PubMed Web of Science ®Google Scholar
• RauePJSchulbergHCHeoMKlimstraSBruceMLPatients’ depression treatment preferences and initiation, adherence, and outcome: a randomized primary care studyPsychiatr Serv20096033734319252046
   PubMed Web of Science ®Google Scholar
• PolsterMZanuttoEMcDonaldSConnerCHammerMA comparison of preferences for two GLP-1 products – liraglutide and exenatide – for the treatment of type 2 diabetesJ Med Econ20101365566121034377
   PubMedGoogle Scholar